What is a stock summary page? Click here for an overview.
Business Description
SpringWorks Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US85205L1070
Share Class Description:
SWTX: Ordinary SharesDescription
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 38.93 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 17.92 | |||||
| Beneish M-Score | 26.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1.3 | |||||
| 3-Year EPS without NRI Growth Rate | 1 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 64.98 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.04 | |||||
| 9-Day RSI | 46.18 | |||||
| 14-Day RSI | 49.39 | |||||
| 3-1 Month Momentum % | 63.67 | |||||
| 6-1 Month Momentum % | 69.43 | |||||
| 12-1 Month Momentum % | 13.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.81 | |||||
| Quick Ratio | 3.7 | |||||
| Cash Ratio | 3.08 | |||||
| Days Inventory | 209.84 | |||||
| Days Sales Outstanding | 47.69 | |||||
| Days Payable | 257.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.7 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.45 | |||||
| Operating Margin % | -145.17 | |||||
| Net Margin % | -134.73 | |||||
| FCF Margin % | -102.46 | |||||
| ROE % | -46.69 | |||||
| ROA % | -40.38 | |||||
| ROIC % | -126.31 | |||||
| 3-Year ROIIC % | -66.69 | |||||
| ROC (Joel Greenblatt) % | -1114.71 | |||||
| ROCE % | -49.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.67 | |||||
| PB Ratio | 7.5 | |||||
| Price-to-Tangible-Book | 7.75 | |||||
| EV-to-EBIT | -12.37 | |||||
| EV-to-EBITDA | -12.52 | |||||
| EV-to-Revenue | 17.95 | |||||
| EV-to-Forward-Revenue | 10.28 | |||||
| EV-to-FCF | -17.97 | |||||
| Price-to-Net-Current-Asset-Value | 13.15 | |||||
| Price-to-Net-Cash | 17.9 | |||||
| Earnings Yield (Greenblatt) % | -8.08 | |||||
| FCF Yield % | -5.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SWTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SpringWorks Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 191.589 | ||
| EPS (TTM) ($) | -3.48 | ||
| Beta | 0.71 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.52 | ||
| Volatility % | 77.32 | ||
| 14-Day RSI | 49.39 | ||
| 14-Day ATR ($) | 2.841997 | ||
| 20-Day SMA ($) | 51.682 | ||
| 12-1 Month Momentum % | 13.19 | ||
| 52-Week Range ($) | 28.21 - 62 | ||
| Shares Outstanding (Mil) | 74.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SpringWorks Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SpringWorks Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
SpringWorks Therapeutics Inc Frequently Asked Questions
What is SpringWorks Therapeutics Inc(SWTX)'s stock price today?
The current price of SWTX is $48.51. The 52 week high of SWTX is $62.00 and 52 week low is $28.21.
When is next earnings date of SpringWorks Therapeutics Inc(SWTX)?
The next earnings date of SpringWorks Therapeutics Inc(SWTX) is 2025-05-02 Est..
Does SpringWorks Therapeutics Inc(SWTX) pay dividends? If so, how much?
SpringWorks Therapeutics Inc(SWTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers